About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of TIL in Advanced Solid Tumors (DFGD) | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGEARLY Phase 1NCT06488950

A Study of TIL in Advanced Solid Tumors (DFGD)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor...

Lead sponsor: Shanghai Juncell Therapeutics•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

GC Clinical

CONTACT

086-18001759113 clinicaltrials@juncell.com

Sponsors

Lead Sponsor

Shanghai Juncell Therapeutics

Collaborators

Eastern Hepatobiliary Surgery Hospital

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•have one the tumor resection for TILs production and successfully produced；
•Age: 18 years to 75years;
•Histologically diagnosed as solid tumors;
•Expected life-span more than 3 months;
•ECOG score 0-1;
•Test subjects have failed standard treatment regimens, and be willing to receive TIL therapy;
•At least 1 evaluable tumor lesion;

Exclusion Criteria

•with other malignant tumors, except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;
•Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;
•Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \< 95%;
•Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;
•Significant cardiovascular anomalies

Related studies

RECRUITINGPhase 1

A Study of DXC014 in Patients With Advanced Solid Tumors.

NCT07177937 · Small Cell Lung Cancer, Melanoma, and more

RECRUITINGPhase 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681 · Solid Tumors, Advanced Solid Tumor

RECRUITINGPhase 1/2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

NCT05919264 · Cancer, Colorectal Cancer, and more

RECRUITINGPhase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more

RECRUITINGPhase 1

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

NCT07387068 · Advanced Solid Tumors

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 16, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseEARLY_PHASE1

Enrollment30

Start dateApr 2023

Last updatedDec 16, 2025

Condition

Advanced Solid Tumor Tumor Infiltrating Lymphocytes Treatment Side Effects Effects of Immunotherapy

Locations shown

Third Affiliated Hospital of Naval Medical University

Shanghai

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 16, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions